이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

백금 민감성 재발성 OC 환자에서 OSE2101 단독 또는 Pembrolizumab 대 BSC와의 병용 (TEDOVA)

2026년 11월 13일 업데이트: ARCAGY/ GINECO GROUP

백금 기반 화학 요법 후 통제된 질병을 앓고 있는 백금 민감성 재발성 난소암 환자에서 유지 치료로서 항 PD1(펨브롤리주맙)을 포함하거나 포함하지 않는 네오 에피토프 기반 백신 OSE2101(TEDOPI®)과 최상의 지지 요법을 비교하는 무작위 2상 연구

The proposed study is an international randomized phase II, multicenter, open-label, three arms trial to assess best supportive care (BSC) vs OSE2101 and vs OSE2101 + pembrolizumab as maintenance treatment for patients with platinum sensitive relapsed ovarian cancers, previously treated with chemotherapy (regardless of the number of prior lines of platinum-based chemotherapy), bevacizumab (if eligible) and a PARP inhibitor (if eligible).

Patients in Complete Response, Partial Response, or Stable Disease at the end of chemotherapy with at least 4 cycles of platinum based chemotherapy will be randomized in one of the three arms (randomization 1:1:2). They will receive one or the two study treatments or BSC until progression, or intolerance, or up to 2 years (from 1st study treatment dose).

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

The only therapeutic option for ovarian cancer patients presenting platinum sensitive relapse post- both bevacizumab and a PARPi is a platinum combination x 6 cycles followed by observation. There is no currently approved maintenance therapy in this setting. There is an urgent need for novel strategies for OC in relapse post bevacizumab and PARPi, in particular for novel maintenance strategies to prolong chemotherapy-free intervals.

One attractive strategy to turn OC from 'cold' tumors into a 'hot' tumor is via vaccination with tumor associated, or specific epitopes that have been modified to increase MHC and TCR binding.

OSE2101 is a multi-neoepitope vaccine covering relevant TAAs in OC, including p53 (mutated in 95% of high-grade OC). In addition, the combination of OSE2101with an ICI may most effectively harness anti-tumor immunity.

If novel IO approaches are proposed in OC, they should be investigated early in the disease setting when host immunity is still robust, and with low tumor burden (platinum sensitive relapse and after 6 cycles of platinum chemotherapy).

The hypothesis being tested is that OSE2101 alone or in combination with Pembrolizumab as maintenance treatment in patients with ovarian cancer platinum-sensitive relapse could potentially bring benefit to subjects with high unmet medical need.

A total of 180 patients with HLA-A2 positive phenotype will be randomized using an Interactive Web Response System (IWRS) according to the following stratification factor:

• Best response to platinum therapy: SD vs PR/CR

In a 1:1:2 ration on the 3 study arms:

  • Arm A (n=45): Observation/best supportive care
  • Arm B (n=45): OSE2101: every 3 weeks until week 18, then every 6 weeks up to week 48, then every 12 weeks until disease progression, intolerance, patient withdrawal of consent or up to 2 years
  • Arm C (n=90): OSE2101 + Pembrolizumab: OSE2101 same schedule as arm B plus pembrolizumab IV every 6 weeks until disease progression, intolerance, patient withdrawal of consent or up to 2 years

Patient with phenotype HLA-A2 negative will be followed in a separate cohort to record treatment and outcomes.

연구 유형

중재적

등록 (실제)

185

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Dresden, 독일, 01307
        • Universitätsklinikum Carl Gustav Carus
      • Essen, 독일, 45136
        • Evang. Kliniken Essen-Mitte GmbH
      • Leipzig, 독일, 04103
        • Universitätsklinikum Leipzig
      • Mainz, 독일, 55131
        • Universitätsmedizin Mainz
      • Mannheim, 독일, 68167
        • Universitätsmedizin Mannheim GmbH
      • Ulm, 독일, 89075
        • Universitätsklinikum Ulm
      • Leuven, 벨기에, 3000
        • UZ Leuven
      • Libramont, 벨기에, 6800
        • Centre Hospitalier de l'Ardenne Vivalia
      • Liège, 벨기에, 4000
        • Centre Hospitalier Universitaire de Liège
      • Angers, 프랑스, 49055
        • ICO Paul Papin
      • Avignon, 프랑스, 84000
        • Institut du Cancer Avignon-Provence
      • Bayonne, 프랑스, 64109
        • Centre Hospitalier de la Côte Basque
      • Besançon, 프랑스, 25030
        • CHU Besançon - Hôpital Jean Minjoz
      • Bordeaux, 프랑스, 33076
        • Institut Bergonié
      • Caen, 프랑스, 14000
        • Centre François Baclesse
      • Chambray-lès-Tours, 프랑스, 37170
        • Centre d'Oncologie et de Radiothérapie 37
      • Cholet, 프랑스, 49300
        • Centre Hospitalier de Cholet
      • Clermont-Ferrand, 프랑스, 63011
        • Centre Jean PERRIN
      • Dijon, 프랑스, 21000
        • Centre Georges François Leclerc
      • Grenoble, 프랑스, 38043
        • CHU Grenoble-Alpes - Site Nord (La Tronche)
      • Lille, 프랑스, 59020
        • Centre Oscar Lambret
      • Limoges, 프랑스, 87042
        • CHU Limoges - Dupuytren
      • Lyon, 프랑스, 69373
        • Centre Léon Bérard
      • Lyon, 프랑스, 69008
        • Hôpital Privé Jean Mermoz
      • Marseille, 프랑스, 13009
        • Institut Paoli Calmettes
      • Montpellier, 프랑스, 34298
        • ICM - Val d'Aurelle
      • Nantes, 프랑스, 44202
        • Hôpital Privé du Confluent
      • Nice, 프랑스, 06100
        • Centre Antoine Lacassagne
      • Paris, 프랑스, 75014
        • Hôpital Cochin
      • Paris, 프랑스, 75013
        • Hôpital Pitié-Salpêtrière - AP-HP
      • Paris, 프랑스, 75020
        • Groupe Hospitalier Diaconesses-Croix Saint-Simon
      • Pau, 프랑스, 64000
        • Center Hospitalier de Pau
      • Pierre-Bénite, 프랑스, 69495
        • Centre Hospitalier Lyon Sud
      • Plérin, 프랑스, 22190
        • Centre CARIO - HPCA
      • Rennes, 프랑스, 35042
        • Centre Eugène Marquis
      • Saint-Herblain, 프랑스, 44805
        • ICO - Centre René Gauducheau
      • Saint-Priest-en-Jarez, 프랑스, 42271
        • CHU de Saint-Etienne - Pôle de Cancérologie
      • St-Malo, 프랑스, 35400
        • Centre Hospitalier Broussais
      • Strasbourg, 프랑스, 67200
        • CHU Strasbourg - Hôpital de Hautepierre
      • Toulouse, 프랑스, 31059
        • Institut Claudius Régaud
      • Villejuif, 프랑스, 94805
        • Gustave Roussy

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  1. Signed and dated informed consent document for the study, willing and able to comply with protocol requirements, including:

    1. HLA-A2 phenotype determination by genetic test (blood)
    2. participation in translational research in HLA-A2 positive
    3. authorization for long term follow up if HLA-A2 negative
  2. Histologically proven non-mucinous epithelial ovarian cancer

  3. Positive HLA-A2 phenotype

  4. Age ≥ 18 years

  5. ECOG Performance Status (PS) 0-1

  6. Clinical or radiological relapse of a platinum sensitive ovarian cancer regardless of the number of prior lines of platinum-based chemotherapy, as long as each prior line fulfilled the platinum sensitive criteria defined as complete response, partial response or stable disease according to RECIST 1.1 at the end of a platinum-based chemotherapy. Patient must have received at least 4 infusions of platinum during the last line of platinum-based chemotherapy

  7. Previously treated with a PARP inhibitor or not eligible to PARPi (i.e ineligibility due to not complete or partial response to chemotherapy)

  8. Prior therapy with bevacizumab or with contra-indication to bevacizumab (i.e arterial thromboembolic events, history of intestinal perforation, any other contra-indications according to the SmPC)

  9. Patient may have received prior immune checkpoint inhibitor (ICI), such as anti-PD-(L)1 or anti-CTLA-4 antibody and had a relapse after receiving the ICI without concomitant chemotherapy for at least 6 months (as treatment or maintenance)

  10. Randomization must be within 8 weeks of last dose of chemotherapy

  11. Adequate organ function Adequate marrow function White blood cell (WBC) ≥ 3000/ mm3 Neutrophils ≥ 1500/ mm3 Platelets ≥ 100 × 103/mm3 (in the absence of transfusion within 2 weeks from before randomization) Haemoglobin ≥ 9 g/dL (in the absence of transfusion within 2 weeks from before randomization) Adequate other organ functions ALT and AST ≤ 2.5 × ULN, unless liver metastases are presents in which case they must be ≤ 5.0 × ULN Total bilirubin ≤ 1.5× ULN (except Gilbert Syndrome: < 3.0 mg/dL)

    Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 40 mL/min (measured using the Cockcroft-Gault formula below):

    Female CrCl = (140 - age in years) × weight in kg × 0.85 72 × serum creatinine in mg/dL

  12. Archival or fresh (if possible) tumor tissue must be available for evaluating relevant biomarkers.

  13. Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to treatment allocation, and have to use of highly effective contraception during the treatment period and for at least 180 days after the last dose of study treatment

  14. Stated willingness to comply with all study procedures and availability for the duration of the study

  15. For countries where this will apply to : a subject will be eligible for randomization in this study only if either affiliated to, or a beneficiary of, a social security category.

Exclusion Criteria:

  1. Patient with contra-indications to immune therapies

  2. Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy that would be scheduled to continue concomitantly to the study)

  3. Use of any of the following immunomodulatory agents within 30 days prior to the first dose of study drug: Systemic corticosteroids (at dose higher than 10 mg/day equivalent prednisone); if systemic corticoid use, corticoid must be stopped at least 7 days before study treatment start Interferons Interleukins Live vaccine

    Note: Examples of live vaccines include, but are not limited to, the following:

    measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed as other killed vaccines, if done at least 2 weeks prior the first dose of study drug; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.

  4. Prior cancer vaccine therapy

  5. Patient eligible for cytoreductive surgery at the time of inclusion

  6. Patient with clinical, radiological or biological progression (according GCIG criteria) at the end of last chemotherapy

  7. Prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.

    A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.

  8. Patient with active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.

  9. History of serious adverse reactions, including anaphylaxis and related symptoms such as hives and respiratory difficulty following administration of any vaccines, or a history of hypersensitivity, specifically to any components of study vaccine

  10. Prior history of other malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or other in situ cancer considered as cured) unless the patient has been free of the disease for at least 5 years.

  11. Immune-deficient status (patients with HIV, immunosuppressive treatment, haematological malignancies, and previous organ transplantation)

  12. History of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease that requires steroids.

  13. History of any chronic hepatitis as evidenced by:

    Positive test for hepatitis B surface antigen Positive test for qualitative hepatitis C viral load (by polymerase chain reaction [PCR]) Note: Subjects with positive hepatitis C antibody and negative quantitative hepatitis C by PCR are eligible. History of resolved hepatitis A virus infection is not an exclusion criterion

  14. Uncontrolled or significant cardiovascular disease including, but not limited to, any of the following: Myocardial infarction or stroke/transient ischemic attack within the past 6 months Uncontrolled angina within the past 3 months History of other clinically significant heart disease (eg, cardiomyopathy, congestive heart failure with New York Heart Association functional classification III-IV, pericarditis, significant pericardial effusion, or myocarditis) Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes) QT interval corrected for heart rate using Fridericia's formula (QTcF) prolongation > 480 msec Cardiovascular disease-related requirement for daily supplemental oxygen therapy

  15. Subjects with known or suspected CNS metastases, untreated CNS metastases, are excluded. However, subjects with controlled brain metastases will be allowed to enroll. Controlled brain metastases are defined as no radiographic progression for at least 4 weeks following radiation and/or surgical treatment (or 4 weeks of observation if no intervention is clinically indicated), and off of steroids for at least 2 weeks, and no new or progressive neurological signs and symptoms.

  16. Any major surgery within 4 weeks of study drug administration. Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before date of randomization.

  17. Patients who has severe hypersensitivity (Grade 3 or higher) to pembrolizumab and/or any of its excipients (refer to the IB for a list of excipients).

  18. Patients who has an active infection requiring systemic therapy.

  19. Any acute medical condition that in the opinion of the investigator may obscure the ability to observe the safety or activity of the study vaccine treatment

  20. Any mental or psychiatric condition that, in the opinion of the investigator, is likely to compromise the ability to adhere to the protocol schedule

  21. Life expectancy of less than 12 weeks

  22. Pregnant or breastfeeding women

  23. Concurrent participation in any other investigational study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
간섭 없음: Arm A : Best Supportive Care

Observational arm (Standard of care)

실험적: Arm B : OSE2101

OSE2101 monotherapy - subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.

OSE2101 vaccine is an emulsion of peptides suspension in in Montanide® ISA 51 adjuvant and containing 0.5 mg/mL of each 10 synthetically manufactured peptides (5.0 mg/mL total peptide) in 1.5 mL of emulsion.

subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.

다른 이름들:
  • 테도피®
실험적: Arm C : OSE2101 + Pembrolizumab

OSE2101 (subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years) + pembrolizumab (400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.

subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.

다른 이름들:
  • 테도피®

400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.

다른 이름들:
  • MK-3475
  • 키트루다®

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression free survival (PFS)
기간: from date to randomization to date of event, assessed up to 4 years

Progression-free survival (PFS) is the time from randomization to progression measured radiologically using RECIST v1.1 guidelines as reported by the investigator or death, whatever the cause, whichever comes first. Patients alive and free of progression at the cut-off date will be censored at the last tumor assessment date

from date to randomization to date of event, assessed up to 4 years

2차 결과 측정

결과 측정
측정값 설명
기간
Objective response rate (ORR)
기간: from date to randomization to date of event, assessed up to 4 years

Objective response rate is defined using RECIST v1.1. Best overall response is defined as the best radiological response observed over the whole evaluation period before progression or subsequent anti-cancer treatment. Proportion of partial and complete responses over the treated population will be computed.

from date to randomization to date of event, assessed up to 4 years
Incidence of treatment emergent adverse events
기간: from date to randomization to date of study end, assessed up to 4 years

Incidence of treatment emergent adverse events will be assessed based on NCI CTC-AE version 5.0 grade and according MedDRA terms (version 23.0)

from date to randomization to date of study end, assessed up to 4 years
Time to subsequent first treatments (TTST-1)
기간: from date to randomization to date of event, assessed up to 4 years

Time to subsequent treatment (TTST) is the time from randomization to initiation of a first subsequent treatment (including treatment change due to toxicity or investigator's decision). Deaths will be counted as events. Patients alive and not receiving a subsequent treatment will be censored at the last assessment date.

from date to randomization to date of event, assessed up to 4 years
Time to subsequent second treatments (TTST-2)
기간: from date to randomization to date of event, assessed up to 4 years

Time to subsequent treatment (TTST) is the time from randomization to initiation of second subsequent treatment (including treatment change due to toxicity or investigator's decision). Deaths will be counted as events. Patients alive and not receiving a subsequent treatment will be censored at the last assessment date.

from date to randomization to date of event, assessed up to 4 years
Overall Survival (OS)
기간: from date to randomization to death from any cause, assessed up to 4 years

Overall Survival (OS) is defined as time from randomization to the date of death, whatever the cause. Patients alive at the cut-of date will be censored at the last date they are known to be alive

from date to randomization to death from any cause, assessed up to 4 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Alexandra LEARY, MD,PHD, GINECO - Gustave Roussy

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 8월 5일

기본 완료 (실제)

2025년 12월 15일

연구 완료 (실제)

2026년 11월 9일

연구 등록 날짜

최초 제출

2021년 1월 14일

QC 기준을 충족하는 최초 제출

2021년 1월 15일

처음 게시됨 (실제)

2021년 1월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 13일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • GINECO-OV244b
  • 2020-004364-25 (EudraCT 번호)
  • ENGOT-ov58 (기타 식별자: ENGOT)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .